Dr. Thomas Höger
Chief Executive Officer / CFO
Apogenix: APG101 – A Novel Approach for the Treatment of Cancer
APG101 is a human fusion protein consisting of the extracellular domain of the CD95 receptor fused to the IgG part of an antibody. It binds to the CD95 ligand, thereby blocking the interaction with its cognate receptor. Whereas this interaction triggers apoptosis in many cells, it stimulates invasive growth in cancer cells. Blocking CD95 mediated tumor growth thus represents a novel concept to treating cancer.
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation.
This broadcast is hosted, streamed and brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.
The information, statements and opinions contained in this broadcast do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.
Any statements, information and opinions contained in this broadcast, in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend projections and any estimated earnings are or may contain certain forward looking statements and as such involve risks and uncertainties.
Actual results and developments may differ materially from those expressed or implied by these statements depending on a variety of factors.